Company / R&D Expense
Cyclerion Therapeutics, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$959.0K
FY2025
5-year range
$959.0K / $56.4M
FY2021-FY2025
Trend
-36.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6M to $959,000 over the past 2 years.
Based on SEC 10-K filings.
$959,000 in FY2025 with a 5-year CAGR of -60.1%.
Declined from $6M to $959,000 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -45.7%
- 5-Year CAGR
- -60.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -60.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 36.7% year-over-year.
- Peak r&d expense was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -19.82 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $959.0K | -36.7% |
| FY2024 | $1.5M | -74.7% |
| FY2023 | $6.0M | +0.0% |
| FY2022 | $6.0M | -89.4% |
| FY2021 | $56.4M | -40.7% |
| FY2020 | $95.1M | +8.5% |
| FY2019 | $87.7M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026